@article{TCR8773,
author = {Chen-Hua Liu and Jia-Horng Kao},
title = {Hepatocellular carcinoma recurrence after interferon-free direct acting antiviral treatment for chronic hepatitis C virus infection: fact or fiction?},
journal = {Translational Cancer Research},
volume = {5},
number = {Suppl 2},
year = {2016},
keywords = {},
abstract = {Hepatitis C virus (HCV) infection is the leading cause of cirrhosis, hepatic decompensation, hepatocellular carcinoma (HCC) and liver transplantation worldwide (1-3). Compared to HCV-infected patients who fail to achieve sustained virologic response (SVR) following interferon (IFN)-based antiviral therapies, those who achieve SVR have decreased long-term morbidity and mortality (4,5). In recent years, treating HCV with IFN-free direct acting antiviral agents (DAAs) has shown superb efficacy and safety and thus become the current standard of care for HCV infection.},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/8773}
}